Product Surveillance, Postmarketing

"Product Surveillance, Postmarketing" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Surveillance of drugs, devices, appliances, etc., for efficacy or adverse effects, after they have been released for general sale.

Descriptor ID

D011358

MeSH Number(s)

E05.337.800

Concept/Terms

Product Surveillance, Postmarketing

Drug Surveillance, Postmarketing

Below are MeSH descriptors whose meaning is more general than "Product Surveillance, Postmarketing".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Investigative Techniques [E05]
Evaluation Studies as Topic [E05.337]
Product Surveillance, Postmarketing [E05.337.800]

Below are MeSH descriptors whose meaning is related to "Product Surveillance, Postmarketing".

Below are MeSH descriptors whose meaning is more specific than "Product Surveillance, Postmarketing".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Product Surveillance, Postmarketing" by people in Harvard Catalyst Profiles by year, and whether "Product Surveillance, Postmarketing" was a major or minor topic of these publication.

Bar chart showing 262 publications over 31 distinct years, with a maximum of 30 publications in 2012 and 2013

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1990	4	1	5
1991	1	3	4
1992	1	0	1
1993	1	1	2
1994	2	0	2
1995	0	1	1
1996	1	2	3
1997	0	1	1
1998	0	1	1
1999	1	0	1
2000	0	1	1
2001	1	1	2
2002	2	1	3
2003	0	4	4
2004	1	1	2
2005	3	4	7
2006	3	2	5
2007	4	5	9
2008	4	6	10
2009	7	4	11
2010	6	3	9
2011	8	7	15
2012	20	10	30
2013	18	12	30
2014	16	6	22
2015	15	7	22
2016	7	4	11
2017	9	7	16
2018	6	11	17
2019	11	3	14
2020	0	1	1

Below are the most recent publications written about "Product Surveillance, Postmarketing" by people in Profiles.

Bhasale A, Mintzes B, Sarpatwari A. Communicating emerging risks of SGLT2 inhibitors-timeliness and transparency of medicine regulators. BMJ. 2020 04 29; 369:m1107.

View in: PubMed
Brennan L, Milad MP, King LP. The Morcellation "Debate" and the FDA 510(k) Process-A Call for Further Reform. Obstet Gynecol Surv. 2019 Dec; 74(12):679-692.

View in: PubMed
Kesselheim AS, Sinha MS, Campbell EG, Schneeweiss S, Rausch P, Lappin BM, Zhou EH, Avorn J, Dal Pan GJ. Multimodal Analysis of FDA Drug Safety Communications: Lessons from Zolpidem. Drug Saf. 2019 11; 42(11):1287-1295.

View in: PubMed
Connolly JG, Schneeweiss S, Glynn RJ, Gagne JJ. Non-Vitamin K Antagonist Oral Anticoagulants and Angioedema: A Cohort and Case-Crossover Study. Drug Saf. 2019 11; 42(11):1355-1363.

View in: PubMed
Cocoros NM, Haynes K, Her Q, Cosgrove A, Dee E, Lin ND, Tu CM, Ding Y, Nguyen M, Toh S. Identification of potential drug name confusion errors in the Sentinel System. Pharmacoepidemiol Drug Saf. 2019 10; 28(10):1405-1410.

View in: PubMed
McMahill-Walraven CN, Kent DJ, Panozzo CA, Pawloski PA, Haynes K, Marshall J, Brown J, Eichelberger B, Lockhart CM. Harnessing the Biologics and Biosimilars Collective Intelligence Consortium to Evaluate Patterns of Care. J Manag Care Spec Pharm. 2019 Nov; 25(11):1156-1161.

View in: PubMed
Ingrasciotta Y, Sultana J, Kirchmayer U, Trifirò G. Challenges in Post-marketing Studies of Biological Drugs in the Era of Biosimilars: A Report of the International Society for Pharmacoepidemiology 2019 Mid-Year Meeting in Rome, Italy. BioDrugs. 2019 Aug; 33(4):345-352.

View in: PubMed
MacDonald SC, Cohen JM, Panchaud A, McElrath TF, Huybrechts KF, Hernández-Díaz S. Identifying pregnancies in insurance claims data: Methods and application to retinoid teratogenic surveillance. Pharmacoepidemiol Drug Saf. 2019 09; 28(9):1211-1221.

View in: PubMed
Stern AD, Gordon WJ, Landman AB, Kramer DB. Cybersecurity features of digital medical devices: an analysis of FDA product summaries. BMJ Open. 2019 06 28; 9(6):e025374.

View in: PubMed
Barrett JS, Heaton PM. Real-World Data: An Unrealized Opportunity in Global Health? Clin Pharmacol Ther. 2019 07; 106(1):57-59.

View in: PubMed

Related Networks

People

Explore

Similar Concepts

Top Journals

Pharmacoepidemiol Drug Saf
JAMA
Clin Pharmacol Ther
N Engl J Med
BMJ
Epidemiology
Drug Saf
Am J Epidemiol
Vaccine
Circulation